The Metastatic Renal Cell Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Renal Cell Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued products.
GlobalData tracks 144 drugs in development for Metastatic Renal Cell Carcinoma by 113 companies/universities/institutes. The top development phase for Metastatic Renal Cell Carcinoma is phase ii with 63 drugs in that stage. The Metastatic Renal Cell Carcinoma pipeline has 138 drugs in development by companies and six by universities/ institutes. Some of the companies in the Metastatic Renal Cell Carcinoma pipeline products market are: Bristol-Myers Squibb, Merck and F. Hoffmann-La Roche.
The key targets in the Metastatic Renal Cell Carcinoma pipeline products market include Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor, and Vascular Endothelial Growth Factor Receptor 2.
The key mechanisms of action in the Metastatic Renal Cell Carcinoma pipeline product include Programmed Cell Death Protein 1 Antagonist with 16 drugs in Pre-Registration. The Metastatic Renal Cell Carcinoma pipeline products include 14 routes of administration with the top ROA being Intravenous and 12 key molecule types in the Metastatic Renal Cell Carcinoma pipeline products market including Monoclonal Antibody, and Small Molecule.
Metastatic Renal Cell Carcinoma overview
Metastatic Renal Cell Carcinoma (mRCC) refers to advanced kidney cancer where cancer cells originating in the kidneys have spread to other parts of the body. Renal cell carcinoma (RCC) is the most common type of kidney cancer. In metastatic cases, cancer cells may spread to distant organs, such as the lungs, bones, or liver, and potentially lymph nodes. Symptoms may include weight loss, fatigue, pain, and blood in the urine. Diagnosis involves imaging studies like CT scans, MRIs, and sometimes biopsy for confirmation. Treatment for metastatic renal cell carcinoma often includes targeted therapies, immunotherapy, and occasionally surgery or radiation to manage symptoms. The choice of treatment depends on the extent of metastasis, the overall health of the patient, and specific characteristics of the cancer. Regular monitoring and a collaborative, multidisciplinary approach are essential for managing metastatic renal cell carcinoma effectively.
For a complete picture of Metastatic Renal Cell Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
